Trial Profile
Phase I study of 5-FU + Oxaliplatin + Irinotecan + Levofolinate + Panitumumab as the first-line therapy in patients with KRAS or RAS wild-type metastatic colorectal cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Mar 2018
Price :
$35
*
At a glance
- Drugs Fluorouracil (Primary) ; Irinotecan (Primary) ; Levofolinic acid (Primary) ; Oxaliplatin (Primary) ; Panitumumab (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- Acronyms JACCRO CC-14
- 08 Mar 2018 Status changed from active, no longer recruiting to completed.
- 15 Nov 2016 Status changed from recruiting to active, no longer recruiting.
- 05 Nov 2014 New trial record